Unique ID issued by UMIN | UMIN000017342 |
---|---|
Receipt number | R000020122 |
Scientific Title | Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers |
Date of disclosure of the study information | 2015/05/01 |
Last modified on | 2018/11/01 10:36:44 |
Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers
Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers
Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers
Verification of the effect of lubiprostone on intestinal permeability in healthy volunteers
Japan |
Healthy Volunteers
Gastroenterology | Adult |
Others
NO
The efficiency of Lubiprostone in intestinal permeability
Pharmacodynamics
Exploratory
Permeability of the small intestine using the lactulose/mannitol test
Endotoxin activity in blood, changes in the intestinal flora
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
NO
NO
Institution is not considered as adjustment factor.
YES
Pseudo-randomization
2
Treatment
Medicine |
24mcg of Lubiprostone once daily after lunch for 14 days or 28 days
No treatment for 14 days or 28 days
20 | years-old | <= |
60 | years-old | > |
Male
1)Men at age >=20 years but <60 years when the consent was obtained
2)Persons who were determined to be healthy adults by the investigator/sub-investigator (hereinafter referred to as investigator, etc.) during medical interview at screening
3)Persons from whom the written consent was obtained and who can abide by the compliance rules while participating in this study, receive medical examination and tests prescribed in this protocol, and report symptoms, etc.
1)Persons who have received NSAIDs within 3 months before obtaining the consent (excluding topical administration of NSAIDs)
2)Persons with history of food or drug allergy (diclofenac sodium, lubiprostone, etc.) or who are suspected of such allergy
3)Persons with current or history of serious cardiovascular/vascular, hematological, respiratory, liver, kidney, gastrointestinal, or neuropsychiatric disease
4)Persons who are taking proton pump inhibitors (PPIs), antibiotics, or intestinal drugs (excluding topical administration of antibiotics)
5)Persons who have participated in other clinical studies and received the study drug, etc. within 1 month prior to the start of this study (calculated from the administration date of the study drug)
6)Persons who were judged by the investigator, etc. to be inappropriate as a subject for this study
35
1st name | |
Middle name | |
Last name | Hiroki Endo |
Yokohama City University
Department of Gastroenterology and Hepatology
3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan
045-787-2800ext.6600
endo1978@yokohama-cu.ac.jp
1st name | |
Middle name | |
Last name | Hiroki Endo |
Yokohama City University
Department of Gastroenterology and Hepatology
3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, Japan
045-787-2800ext.6600
endo1978@yokohama-cu.ac.jp
Yokohama City University School of Medicine Department of Gastroenterology and Hepatology
Abbott Japan Co., Ltd
Profit organization
NO
横浜市立大学附属病院
2015 | Year | 05 | Month | 01 | Day |
Published
https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0175626
Completed
2015 | Year | 03 | Month | 26 | Day |
2015 | Year | 05 | Month | 11 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 03 | Month | 31 | Day |
2016 | Year | 03 | Month | 31 | Day |
2015 | Year | 04 | Month | 30 | Day |
2018 | Year | 11 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020122